280Bio

280Bio, Inc., headquartered in the San Francisco Bay Area, is developing innovative precision small-molecule inhibitors for cancer treatment. 280Bio's pipeline focuses on novel oral oncology candidates, primarily targeting frequently mutated genetic alterations in signaling pathways and known genomic instability characteristics of many cancers. The company is advancing its development programs through a strategic collaboration with MD Anderson Cancer Center and a partnership with Yingli Pharma. 280Bio is developing its candidate drugs for monotherapy and combination treatments in solid tumors and hematologic malignancies.